Jeff Yass’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-280,600
| Closed | -$11.3M | – | 13332 |
|
|
2026
Q1 | $11.3M | Sell |
280,600
-376,600
| -57% | -$8.12M | ﹤0.01% | 2931 |
|
|
2025
Q4 | $16.5M | Buy |
657,200
+188,200
| +40% | +$4.42M | ﹤0.01% | 2420 |
|
|
2025
Q3 | $10.6M | Sell |
469,000
-47,800
| -9% | -$1.11M | ﹤0.01% | 2967 |
|
|
2025
Q2 | $8.95M | Buy |
516,800
+193,300
| +60% | +$3.58M | ﹤0.01% | 2989 |
|
|
2025
Q1 | $7.07M | Sell |
323,500
-535,700
| -62% | -$14.8M | ﹤0.01% | 3020 |
|
|
2024
Q4 | $27.4M | Buy |
859,200
+71,700
| +9% | +$2.16M | ﹤0.01% | 1607 |
|
|
2024
Q3 | $22.7M | Sell |
787,500
-241,300
| -23% | -$8.94M | ﹤0.01% | 1705 |
|
|
2024
Q2 | $39.5M | Buy |
1,028,800
+707,000
| +220% | +$32M | 0.01% | 1144 |
|
|
2024
Q1 | $18.9M | Sell |
321,800
-623,900
| -66% | -$39.8M | ﹤0.01% | 1845 |
|
|
2023
Q4 | $56.6M | Sell |
945,700
-74,000
| -7% | -$3.75M | 0.01% | 969 |
|
|
2023
Q3 | $38.8M | Buy |
1,019,700
+864,700
| +558% | +$38M | 0.01% | 1194 |
|
|
2023
Q2 | $14.1M | Sell |
155,000
-203,200
| -57% | -$17.5M | ﹤0.01% | 2090 |
|
|
2023
Q1 | $23.6M | Buy |
358,200
+170,400
| +91% | +$9.83M | 0.01% | 1542 |
|
|
2022
Q4 | $9.71M | Buy |
187,800
+24,500
| +15% | +$1.3M | ﹤0.01% | 2311 |
|
|
2022
Q3 | $11.2M | Buy |
163,300
+132,300
| +427% | +$7.83M | ﹤0.01% | 2021 |
|
|
2022
Q2 | $1.4M | Sell |
31,000
-148,500
| -83% | -$6.77M | ﹤0.01% | 5711 |
|
|
2022
Q1 | $9.12M | Buy |
179,500
+78,200
| +77% | +$3.45M | ﹤0.01% | 2672 |
|
|
2021
Q4 | $4.79M | Sell |
101,300
-425,500
| -81% | -$16.8M | ﹤0.01% | 3814 |
|
|
2021
Q3 | $17.4M | Buy |
526,800
+69,100
| +15% | +$3.88M | ﹤0.01% | 2139 |
|
|
2021
Q2 | $28.9M | Buy |
457,700
+333,200
| +268% | +$17.2M | ﹤0.01% | 1639 |
|
|
2021
Q1 | $5.34M | Buy |
124,500
+24,700
| +25% | +$1.17M | ﹤0.01% | 3787 |
|
|
2020
Q4 | $5.71M | Buy |
99,800
+23,900
| +31% | +$1.01M | ﹤0.01% | 3222 |
|
|
2020
Q3 | $2.29M | Buy |
75,900
+55,600
| +274% | +$1.66M | ﹤0.01% | 4364 |
|
|
2020
Q2 | $663K | Sell |
20,300
-22,300
| -52% | -$716K | ﹤0.01% | 6763 |
|
|
2020
Q1 | $1.14M | Sell |
42,600
-113,200
| -73% | -$4.02M | ﹤0.01% | 5094 |
|
|
2019
Q4 | $4.77M | Buy |
155,800
+82,100
| +111% | +$2.27M | ﹤0.01% | 3029 |
|
|
2019
Q3 | $1.77M | Buy |
+73,700
| New | +$2.03M | ﹤0.01% | 4452 |
|
Other funds holding APLS
Jeff Yass's APLS Position: Q2 2026 in Review
Jeff Yass sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 340,086 shares — an estimated $13.7M sold.
Jeff Yass first reported a position in APLS in Q2 2019 and held it in 28 quarters. The position peaked at $28.8M in Q2 2023. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Jeff Yass reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Jeff Yass sold 340,086 Apellis Pharmaceuticals shares in Q2 2026, an estimated $13.7M.
- Jeff Yass first reported a position in Apellis Pharmaceuticals in Q2 2019 and held it in 28 quarters.
- Jeff Yass's Apellis Pharmaceuticals position peaked at $28.8M in Q2 2023.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.